Page last updated: 2024-08-21

thiazoles and Cutaneous Mastocytosis

thiazoles has been researched along with Cutaneous Mastocytosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Bonkobara, M; Dally, C; Gentilini, F; Kurita, S; Takanosu, M; Turba, ME	1
Essick, L; Legendre, AM; Rohrbach, BW; Smrkovski, OA	1
Barete, S; Casassus, P; Dubreuil, P; Gineste, P; Grandpeix-Guyodo, C; Hermine, O; Lanternier, F; Lortholary, O; Mansfield, CD; Moussy, A; Palmérini, F; Paul, C; Sans, B; Suarez, F	1

Trials

1 trial(s) available for thiazoles and Cutaneous Mastocytosis

Article	Year
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. American journal of hematology, 2010, Volume: 85, Issue:12 Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperidines; Pyridines; Thiazoles; Treatment Outcome	2010

Article

Year

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

American journal of hematology, 2010, Volume: 85, Issue:12

Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperidines; Pyridines; Thiazoles; Treatment Outcome

2010

Other Studies

2 other study(ies) available for thiazoles and Cutaneous Mastocytosis

Article	Year
The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs. BMC veterinary research, 2020, Feb-19, Volume: 16, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; HEK293 Cells; Humans; Mastocytosis, Cutaneous; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Thiazoles; Vinblastine	2020
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Veterinary and comparative oncology, 2015, Volume: 13, Issue:3 Topics: Animals; Benzamides; Disease-Free Survival; Dog Diseases; Dogs; Female; Kaplan-Meier Estimate; Male; Mastocytosis, Cutaneous; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyridines; Schools, Veterinary; Skin Neoplasms; Tennessee; Thiazoles	2015

Article

Year

The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

BMC veterinary research, 2020, Feb-19, Volume: 16, Issue:1

Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; HEK293 Cells; Humans; Mastocytosis, Cutaneous; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Thiazoles; Vinblastine

2020

Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.

Veterinary and comparative oncology, 2015, Volume: 13, Issue:3

Topics: Animals; Benzamides; Disease-Free Survival; Dog Diseases; Dogs; Female; Kaplan-Meier Estimate; Male; Mastocytosis, Cutaneous; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyridines; Schools, Veterinary; Skin Neoplasms; Tennessee; Thiazoles

2015